Chemotherapy, HIV Treatment and Prevention Agents and Hospitals

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Chemotherapy

HIV Treatment and Prevention Agents

Hospitals

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

Pharmacy Times

JUNE 16, 2025

Transportation barriers, as a health-related social need, significantly impact FN rates in chemotherapy patients. Febrile neutropenia (FN) remains a serious and common complication of chemotherapy. A 67% FN rate difference between pegfilgrastim and filgrastim was observed in patients with transportation barriers.

HIV Treatment and Prevention Agents

HIV Treatment and Prevention Agents Chemotherapy Compounding Pharmacies Immunization

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

JUNE 10, 2025

The convenience of once-daily dosing and a rapid IV bolus administration may offer workflow efficiencies in hospital or surgical settings, where minimizing polypharmacy and streamlining medication administration are important goals. 2 REFERENCES 1.

FDA

FDA HIV Treatment and Prevention Agents Compounding Pharmacies Hospitals

Pharmacy Technician Pulse

Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Stay Connected